ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Acorda Therapeutics, Pfizer and UCB side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Acorda Therapeutics×Pfizer×UCB×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Acorda TherapeuticsPfizerUCB
studies on the registry534,072581
open to participants now014624
phase 3 studies under way09920
reach primary completion within a year09114
programswith a study of their own in two yearsnone read91+9 named only16

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAcorda TherapeuticsPfizerUCB
Phase 1–

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

UCB: 8 of its 16 programs at phase 1

  1. cizutamigphase 1
  2. Bimekizumab regimen 3 scphase 1
  3. Cizutamig will be dosed according to the protocol.phase 1
  4. CND261phase 1
  5. CND319phase 1

and 3 more — sign in to see them all

50%
Phase 2–

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

UCB: 3 of its 16 programs at phase 2

  1. galvokimigphase 2
  2. glovadalenphase 2
  3. donzakimigphase 2
19%
Phase 3–

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

UCB: 4 of its 16 programs at phase 3

  1. bimekizumabphase 3
  2. zilucoplanphase 3
  3. dapirolizumab pegolphase 3
  4. Fenfluraminephase 3
25%
Approved, new studies–

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

UCB: 1 of its 16 programs at approved, new studies

  1. rozanolixizumabapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Acorda Therapeutics0 readouts · 0 phase 3············
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
UCB6 readouts · 2 phase 3·

UCB, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. UCB5285phase 1 · Dec 13 · NCT07286682
  2. bimekizumabphase 3 · Dec 21 · NCT06921850
··

UCB, Mar ’27: 1 program whose next study reaches primary completion

  1. zilucoplanphase 3 · Mar 23 · NCT06961747
·

UCB, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. rozanolixizumabapproved, new study · May 6 · NCT05063162
  2. galvokimigphase 2 · May 17 · NCT07277660

UCB, Jun ’27: 1 program whose next study reaches primary completion

  1. CND261phase 1 · Jun 1 · NCT07052032
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Acorda Therapeutics

No programs read for this company.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

UCB

New programs 1

  • UCB0159phase 1 · first study · Sep 24 · Psoriasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionAcorda TherapeuticsPfizerUCB
Dermatitis, Atopic2 of 3 · compare here–

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

UCB in Dermatitis, Atopic: 2 programs

  1. galvokimigphase 2
  2. donzakimigphase 2

Their studies: UCB’s studies of Dermatitis, Atopic in search

COVID-192 of 3 · compare here–

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

UCB in COVID-19: 1 program

  1. zilucoplanphase 3

Their studies: UCB’s studies of COVID-19 in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

UCB in Lupus Erythematosus, Systemic: 2 programs

  1. dapirolizumab pegolphase 3
  2. cizutamigphase 1

Their studies: UCB’s studies of Lupus Erythematosus, Systemic in search

Psoriasis2 of 3 · compare here–

Pfizer in Psoriasis: 1 program

  1. abrocitinibphase 3

Their studies: Pfizer’s studies of Psoriasis in search

UCB in Psoriasis: 2 programs

  1. bimekizumabphase 3
  2. UCB0159phase 1

Their studies: UCB’s studies of Psoriasis in search

Arthritis, Rheumatoid2 of 3 · compare here–

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

UCB in Arthritis, Rheumatoid: 1 program

  1. CND261phase 1

Their studies: UCB’s studies of Arthritis, Rheumatoid in search

Hidradenitis Suppurativa2 of 3 · compare here–

Pfizer in Hidradenitis Suppurativa: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Hidradenitis Suppurativa in search

UCB in Hidradenitis Suppurativa: 1 program

  1. bimekizumabphase 3

Their studies: UCB’s studies of Hidradenitis Suppurativa in search

Multiple Myeloma2 of 3 · compare here–

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

UCB in Multiple Myeloma: 1 program

  1. cizutamigphase 1

Their studies: UCB’s studies of Multiple Myeloma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAcorda TherapeuticsPfizerUCB
CD3E–elranatamabrulecizutamigrule
TNFRSF17–elranatamabrulecizutamigrule
A target, or a pathogen for a vaccine, known for: Acorda Therapeutics 0 of 0 · Pfizer 67 of 91 · UCB 7 of 16 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).